Bolt Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Bolt Biotherapeutics Inc BOLT.OQ reported a quarterly adjusted loss of 29 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of four analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -43 cents to -33 cents per share.

• Revenue fell 76.8% to $1.22 million from a year ago; analysts expected $767.50 thousand.

• Bolt Biotherapeutics Inc's reported EPS for the quarter was a loss of 29 cents​.

• The company reported a quarterly loss of $11.04 million.

• Bolt Biotherapeutics Inc shares had fallen by 10.5% this quarter and lost 33.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 11.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $1.13

This summary was machine generated from LSEG data May 12 at 08:59 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)